An open label SLV308 safety extension to study S308.3.003 in early PD patients - An extension to the Vermeer study
- Conditions
- Parkinson's Disease Early stage
- Registration Number
- EUCTR2006-000859-18-EE
- Lead Sponsor
- Solvay pharmaceuticals
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 225
Inclusion Criteria
- Subjects who have signed informed consent for participation in the extension study.
- Subjects who have completed the S308.3.003 trial.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
1. Subjects with medically relevant abnormal findings (electrocardiogram [ECG], physical examination, AEs) at end of the maintenance phase (Visit M6, Week 24) of study S308.3.003.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method